Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells
Tóm tắt
The H3 histamine receptor is a Gi-coupled GPCR that has been proven to exist in different agonist-induced states, including that defined by the protean agonist proxyfan. Several GPCRs are now known to exist in different states. For some of these, antagonist affinity measurement remain constant regardless of the state of the receptor, for others e.g. the beta-adrenoceptors, the antagonist affinity measurements vary considerably depending on which agonist-dependent state is being identified. The purpose of this study was to examine the antagonist affinity measurements at the Gi-coupling human H3 receptor, paying particular attention to measurements made in the presence of full agonists, partial agonists and the proxyfan protean agonist-induced state of the receptor. CHO cells stably expressing the human histamine H3 receptor and a CRE-SPAP reporter were used. Measurements of CRE-gene transcription and 3H-cAMP accumulation were made. A range of ligands of different agonist efficacies were determined, including some partial agonists e.g. VUF 5681. Unlike other Gi-coupled receptors, no Gs-coupled state of the receptor was detected with these ligands. Antagonist affinity measurements were constant, whether the measurements were made in the presence of a full agonist, a partial agonist or the protean agonist proxyfan. In contrast to all three subtypes of the beta-adrenoceptors, but in keeping with the traditional pharmacological dogma, antagonist affinity measurements remained constant at the human H3 receptor, including the medium-efficacy proxyfan-induced state of the receptor and the VUF5681-induced state of the receptor.
Tài liệu tham khảo
Arunlakshana O, Schild HO: Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959, 14 (1): 48-58.
Ash ASF, Schild HO: Receptors mediating some actions of histamine. Br J Pharmacol Chemother. 1966, 27: 427-439.
Hill SJ: G protein-coupled receptors: past, present and future. Br J Pharmacol. 2006, 147: S27-S37. 10.1038/sj.bjp.0706455.
Black JW, Duncan WAM, Shanks RG: Comparison of some Properties of pronethalol and propranolol. Br J Pharmacol. 1965, 25: 577-591.
Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons ME: Definition and antagonism of histamine H2-receptors. Nature. 1972, 236: 385-390. 10.1038/236385a0.
Granneman JG: The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab. 2001, 280: E199-202.
Molenaar P: The 'state' of beta-adrenoceptors. Br J Pharmacol. 2003, 140: 1-2. 10.1038/sj.bjp.0705420.
Arch JR: Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?. Br J Pharmacol. 2004, 143: 517-518. 10.1038/sj.bjp.0705991.
Pak MD, Fishman PH: Anomalous behaviour of CGP 12177A on beta 1-adrenergic receptors. J Recept Signal Transduction Res. 1996, 16: 1-23. 10.3109/10799899609039938.
Konkar AA, Zhu Z, Granneman JG: Aryloxypropanolamine and catecholamine ligand interactions with the β1-adrenergic receptor: evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther. 2000, 294: 923-932.
Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of β-blockers for the two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002, 135: 451-461. 10.1038/sj.bjp.0704450.
Baker JG, Hall IP, Hill SJ: Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol. 2003, 63: 1312-1321. 10.1124/mol.63.6.1312.
Baker JG: Sites of action of β-ligands at the human β1-adrenoceptor. J Pharmacol Exp Ther. 2005, 313: 1163-1171. 10.1124/jpet.104.082875.
Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP: (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. Mol Pharmacol. 1998, 53: 670-675.
Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M: Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol. 2001, 363: 87-93. 10.1007/s002100000336.
Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ: Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol. 2002, 62: 578-589. 10.1124/mol.62.3.578.
Cordeaux Y, Ijzerman AP, Hill SJ: Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol. 2004, 143: 705-714. 10.1038/sj.bjp.0705925.
Baker JG, Hill SJ: A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor. J Pharmacol Exp Ther. 2007, 320: 218-228. 10.1124/jpet.106.113589.
Baker JG: Evidence for a secondary state of the human β3-adrenoceptor. Mol Pharmacol. 2005, 68: 1645-1655.
Baker JG, Hall IP, Hill SJ: Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: Differences between second messenger and reporter gene responses. Mol Pharmacol. 2003, 64: 679-688. 10.1124/mol.64.3.679.
Azzi M, Charest PG, Angers S, Rosseau G, Kohout T, Bouvier M, Pineryo G: Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA. 2003, 100: 11406-11. 10.1073/pnas.1936664100.
Baker JG, Hall IP, Hill SJ: Agonist and inverse agonist actions of "β-blockers" at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol. 2003, 64: 1357-1369. 10.1124/mol.64.6.1357.
Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyadi L, Luttrell LM, Lefkowitz RJ: Independent β-arrestin 2 and G-protein-mediated pathways for angiotensin II activation of extracellular signal regulated kinase 1 and 2. Proc Natl Acad Sci USA. 2003, 100: 10782-10787. 10.1073/pnas.1834556100.
Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ: Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol. 2007, 72: 1359-1368. 10.1124/mol.107.035337.
Baker JG: A study of antagonist affinities for the human histamine H2 receptor. British Journal of Pharmacology.
Parsons ME, Ganellin CR: Histamine and its receptors. Br J Pharmacol. 2006, 147: S127-35. 10.1038/sj.bjp.0706440.
Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983, 302: 832-837. 10.1038/302832a0.
Arrang J-M, Garbarg M, Lancelo J-C, Lecomte J-M, Pollard H, Robba M, Schunack W, Schwartz J-C: Highly potent and selective ligands for histamine H3-receptors. Nature. 1987, 327: 117-123. 10.1038/327117a0.
Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG: Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol. 1999, 55: 1101-1107.
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL: International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharmacol Rev. 1997, 49: 253-278.
Bongers G, Bakker RA, Leurs R: Molecular aspects of the histamine H3 receptor. Biochem Pharmacol. 2007, 73: 1195-1204. 10.1016/j.bcp.2007.01.008.
Kenakin T: Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001, 15: 598-611. 10.1096/fj.00-0438rev.
Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM: Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA. 2003, 100: 11086-11091. 10.1073/pnas.1932276100.
Donaldson J, Brown AM, Hill SJ: Influence of rolipram on the cyclic-3',5'-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem Pharmacol. 1988, 37: 715-723. 10.1016/0006-2952(88)90146-3.
Stephenson RP: A modification of receptor theory. Br J Pharmacol. 1956, 11: 5109-5116.
Qiu R, Melmon KL, Khan MM: Effects of histamine-trifluoromethyl-toluidide derivative (HTMT) on intracellular calcium in human lymphocytes. J Pharmacol Exp Ther. 1990, 253: 1245-52.
Martínez-Mir MI, Estañ L, Morales-Olivas FJ, Rubio E: Effect of histamine and histamine analogues on human isolated myometrial strips. Br J Pharmacol. 1992, 107: 528-531.
Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, Menge WM, Timmerman H, Lovenberg TW, Leurs R: Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001, 299: 908-14.
Baker JG, Hill SJ: Multiple GPCR conformations and signalling pathways: implications for antagonist affinity measurements. Trends Pharmacol Sci. 2007, 28: 274-381. 10.1016/j.tips.2007.06.011.
Zirihi GN, Grellier P, Guede-Guina F, Bodo B, Mambu L: Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. Bioorg Med Chem Lett. 2005, 15: 2637-2640. 10.1016/j.bmcl.2005.03.021.
Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA: A new family of histamine H-3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series. Inflammation Research. 2007, 56 (Suppl 1): S47-S48. 10.1007/s00011-006-0523-9.
Lim HD, Smits RA, Bakker RA, van Dam CM, de Esch IJ, Leurs R: Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem. 2006, 49: 6650-6651. 10.1021/jm060880d.
Kitbunnadaj R, Zuiderveld OP, De Esch IJ, Vollinga RC, Bakker R, Lutz M, Spek AL, Cavoy E, Deltent MF, Menge WM, Timmerman H, Leurs R: Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003, 46: 5445-5457. 10.1021/jm030905y.
Kitbunnadaj R, Zuiderveld OP, Christophe B, Hulscher S, Menge WM, Gelens E, Snip E, Bakker RA, Celanire S, Gillard M, Talaga P, Timmerman H, Leurs R: Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist. J Med Chem. 2004, 47: 2414-7. 10.1021/jm049932u.
Moreno-Delgado D, Torrent A, Gomez-Ramirez J, de Esch I, Blanco I, Ortiz J: Constitutive activity of H-3 autoreceptors modulates histamine synthesis in rat brain through the cAMP/PKA pathway. Neuropharmacology. 2006, 51: 517-523. 10.1016/j.neuropharm.2006.04.010.
January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, Clark RB: β2-adrenergic receptor desensitization, internalization and phosphorylation in response to full and partial agonists. J Biol Chem. 1997, 272: 23871-23879. 10.1074/jbc.272.38.23871.
Clark RB, Knoll BJ, Barber R: Partial agonists and G-protein coupled receptor desensitization. Trends Pharmacol Sci. 1999, 20: 279-286. 10.1016/S0165-6147(99)01351-6.